Guardant Health, Inc.
GH
Rank in Stocks
#1087
Guardant Health, Inc., established in Redwood City, California, in 2011, is a... Guardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals. Another emerging solution in development is GuardantConnect, an integrated software platform intended to link biopharmaceutical and clinical clients by connecting patients whose Guardant360 tests reveal actionable alterations with potentially relevant clinical trials. Furthermore, Guardant Health offers the Guardant Reveal Test, which aids in selecting neoadjuvant and adjuvant treatments for early-stage cancer patients. Its portfolio also includes a Guardant360 product for tissue genotyping and Guardant-19 for novel coronavirus detection. The company extends its expertise to biopharmaceutical companies and medical institutions through various development services, encompassing companion diagnostic development, regulatory approval support, clinical study management (including setup, monitoring, and maintenance), testing development, and kit fulfillment.
Share Price
$159.93
Market Cap
$21.46B
Change (1 day)
0.84%
Change (1 year)
144.32%
Country
US
Trade Guardant Health, Inc. (GH)
Category
Healthcare
P/E ratio for Guardant Health, Inc. (GH)
P/E ratio as of October 2026 TTM: -46.70
According to Guardant Health, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -46.70. At the end of 2023 the company had a P/E ratio of -6.32.
P/E ratio history for Guardant Health, Inc. from 2016 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -46.70 | 443.68% |
| 2024 | -8.59 | 36.01% |
| 2023 | -6.32 | 48.81% |
| 2022 | -4.25 | -83.00% |
| 2021 | -24.98 | -49.55% |
| 2020 | -49.52 | -47.09% |
| 2019 | -93.58 | 149.04% |
| 2018 | -37.58 | 37.33% |
| 2017 | -27.36 | 196.49% |
| 2016 | -9.23 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 36.15 | -177.42% |
US
|
|
| 39.77 | -185.16% |
US
|
|
| -290.26 | 521.51% |
US
|
|
| - | - |
CN
|
|
| 34.18 | -173.20% |
US
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.